



EP 04/10938



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED, IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road

Newport
South Wales

NP 10 800

REC'D 28 DEC 2004

WIPS

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated


23 September 2004







The
**Patent
Office**



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

- 1 OCT 2003

The Patent Office

Cardiff Road
Newport
South Wales NP10 8QQ

1.	Your reference	4-33386P1		
2.	Patent application number <i>(The Patent Office will fill in this part)</i>	0322994.5		
3.	Full name, address and postcode of the or of each applicant <i>(underline all surnames)</i>	NOVARTIS AG LICHTSTRASSE 35 4056 BASEL SWITZERLAND		
	Patent ADP number <i>(if you know it)</i>			
	If the applicant is a corporate body, give the country/state of its incorporation	SWITZERLAND		7125487005
4.	Title of invention	Organic Compounds		
5.	Name of your agent <i>(If you have one)</i> "Address for service" in the United Kingdom to which all correspondence should be sent <i>(including the postcode)</i>	Craig McLean Novartis Pharmaceuticals UK Limited Patents and Trademarks Wimblehurst Road Horsham, West Sussex RH12 5AB		
	Patents ADP number <i>(if you know it)</i>	07181522002		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and <i>(if you know it)</i> the or each application number	Country	Priority application number <i>(if you know it)</i>	Date of filing <i>(day/month/year)</i>
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing <i>(day/month/year)</i>	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? <i>(Answer 'Yes' if:</i> a) <i>any applicant named in part 3 is not an inventor, or</i> b) <i>there is an inventor who is not named as an applicant, or</i> c) <i>any named applicant is a corporate body.</i> <i>-(see note-(d))</i>	Yes		

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 8

Claim(s) 2

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) 1

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application

Signature

Date



Craig McLean

1st October 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr. Trevor Drew

01403 323069

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.


- 1 -

Organic Compounds

The present invention relates to novel fatty acid esters of the reversible loperidone metabolite P-88-8991, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.


loperidone is an atypical antipsychotic developed for the treatment of schizophrenia, having relevant affinity for noradrenergic, dopaminergic and serotonergic receptors. See for example Richelson E. and Souder T., Life Sciences, 68:29-39 (2000).

loperidone is metabolized in a reversible manner to P-88-8991 having the formula II



See for example Mutlib AE et al., Drug Metab. Dispos; 23(9):951-964 (1995). P-88-8991 has been shown to have plasma levels in human about 1.5 fold higher than the parent drug. It is roughly as active as loperidone.

More particularly, the invention relates to compounds of formula I




wherein R is (C₁₋₄₀)alkyl or (C₁₋₄₀)alkenyl, in free base or acid addition-salt form.

On account of the asymmetrical carbon atom which is present in the compounds of formula I, the compounds may exist in optically active form or in form of mixtures of optical isomers,

e.g. in form of racemic mixtures. All optical isomers and their mixtures including the racemic mixtures are part of the present invention.

In a further aspect, the invention provides a process for the production of the compounds of formula I and their salts, comprising the step of reacting the metabolite P-88-8991 of formula II with a compound of formula III



wherein R is as defined above and X is halogen, and recovering the so obtained compound of formula I in free base or acid addition salt form.


The reaction can be effected according to conventional methods, e.g. as described in Example 1.

In formula III, X is preferably chlorine or bromine.

Working up the reaction mixtures and purification of the compounds thus obtained may be carried out in accordance to known procedures.


Acid addition salts may be produced from the free bases in known manner, and vice-versa. Suitable acid addition salts for use in accordance with the present invention include for example the hydrochloride.

The starting compounds of formula II may be obtained by reducing lloperidone of formula IV




with an enantiomer of the boran complex of formula V


- 3 -



The compound of formula II (S)-1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]propoxy}-3-methoxy-phenyl)-ethanol is obtained using the reagent (R)-2-methyl-CBS-oxazaborolidine-borane complex of formula Va





whereas the compound of formula II (R)-1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]propoxy}-3-methoxy-phenyl)-ethanol is obtained using the reagent (S)-2-methyl-CBS-oxazaborolidine-borane complex of formula Vb



The reactions can be effected according to conventional methods, e.g. as described in Example-1.

The borane complexes used as starting materials can be produced from the corresponding compounds of formula VIa and VIb



according to known procedures, e.g. as described in Example 1.

The starting materials of formulae VIa and VIb are known (for a review of these catalysts, see Corey, E. et al., *Angew. Chem., Int. Ed. Engl.* 1998, 37, 1986).

The compounds of formula I and their pharmaceutically acceptable acid addition salts, hereinafter referred to as agents of the invention, exhibit valuable pharmacological properties when tested in animals, and are therefore useful as pharmaceuticals.

In particular, the agents of the invention exhibit antipsychotic and anti-manic activity, as assessed in standard tests such as the amphetamine-induced hypermotility and the phencyclidine-induced hyperlocomotion tests.

The amphetamine-induced hypermotility test is performed according to the method described by Arnt J in *Eur. J. Pharmacol.* 283, 55-62 (1995). In this test, the agents of the invention significantly inhibit the amphetamine-induced locomotion of the animals at doses of about 0.01 to about 10 mg/kg s.c.

The phencyclidine-induced hyperlocomotion test is performed according to a rat adaptation of the method described by Gleason SD and Shannon HE in *Psychopharmacol.* 129, 79-84 (1997). In this test, the agents of the invention significantly block the phencyclidine-induced hyperlocomotion of the rats at doses of about 0.01 to about 10 mg/kg s.c.

The agents of the invention are therefore useful for the treatment of psychotic disorders such as schizophrenia and bipolar disorders.

It has been found that the agents of the invention are enzymatically metabolized into the active compound of formula II which is believed to be predominantly responsible of the in vivo activity in the above-mentioned tests. This ester cleavage has been found to proceed at slow rate. The agents of the invention are therefore of particular interest for use in pharmaceutical compositions aimed at providing a slow release of the compound of formula II.

For the above-mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 500, preferably from about 0.5 to about 100 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 10 to about 2000, preferably from about 100 to about 1000 mg of an agent of the invention, conveniently administered, for example, in divided doses up to four times a day or in sustained release form.

The agent of the invention may be administered by any conventional route, preferably parenterally, for example in the form of injectable solutions or suspensions for intramuscular administration, or transdermally.

In accordance with the foregoing, the present invention also provides an agent of the invention, for use as a pharmaceutical, e.g. for the treatment of psychotic disorders.

The present invention furthermore provides a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured in conventional manner. Unit dosage forms contain, for example, from about 0.25 to about 150, preferably from 0.25 to about 25 mg of a compound according to the invention.

Moreover the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of psychotic disorders.

In still a further aspect the present invention provides a method for the treatment of psychotic disorders, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.

The following examples illustrate the invention.

Example 1:**(S)-(-)-Decanoic acid 1-(4-{3-[4-(6-fluoro-benzo[d]isoxazole-3-yl)-piperidine-1-yl]-propoxy}-3-methoxy-phenyl)-ethyl ester**

- a) 200. ml of a solution of (3aR)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole (1M in toluene) is stirred at room temperature under nitrogen. 1.2 equivalent borane-dimethylsulfide complex is added with a syringe. The solution is stirred for 2 further hours at room temperature. The borane complex is then crystallised by addition of 4 vol dry hexane and cooling to -12°C for 1.5 hour. The product is isolated by filtration in a sintered glass funnel and dried in vacuum at 40°C . The boran complex of (3aR)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole is obtained (white crystals).
- b) 56.36 g of boran complex of (3aR)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole (1 equivalent) is dissolved under nitrogen in methylenchloride, and the solution is cooled to 0°C . A 1M solution of 1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-propoxy}-3-methoxy-phenyl)-ethanone (iloperidone; 1 equivalent) in methylenchloride is added via a dropping funnel over 90 minutes while the internal temperature is maintained at $0^{\circ}\text{C} \pm 2^{\circ}\text{C}$. After the addition is complete, the mixture is stirred at 0°C for 20 hours. The reaction mixture is then poured into precooled methanol ($0-5^{\circ}\text{C}$) during 1 hour. The solution is warmed to room temperature and stirred until the H_2 evolution ceases. The solution is concentrated by distillation and the residue dried in vacuum, treated with methanol and stirred for about 1 hour at 50°C and an additional hour at 0°C . The product is isolated by filtration and dried under reduced pressure for 3 hours at 50°C . (S)-(-)-1-(4-{3-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-propoxy}-3-methoxy-phenyl)-ethanol is obtained (white crystals).

$[\alpha]_{\text{D}}^{20} - 19.3^{\circ}$ (c=1 in chloroform)

Mp: $-138.2 - -138.8^{\circ}\text{C}$

- c) (S)-(-)-1-(4-{3-[4-(6-Fluoro-benzo[d]isoxazole-3-yl)-piperidine-1-yl]-propoxy}-3-methoxy-phenyl)-ethanol (8.57 g, 0.02 mol) is suspended in dichloromethane (150 mL) and pyridine (9.7 mL, 0.02 mol) is added. The reaction mixture is cooled and kept at 0°C .


Subsequently capric acid chloride (16.4 mL, 0.08 mol) is added slowly. The reaction mixture is further stirred at room temperature for 4 hours. The solution is then poured onto ice water and the liquid fractions are being separated. The aqueous fraction is re-extracted with methylenchloride. The combined organic fractions are dried and the solvent evaporated. The crude residue is purified by chromatography (neutral aluminum oxide, activity 3) to give (S)-(-)-decanoic acid 1-(4-{3-[4-(6-fluoro-benzo[d]isoxazole-3-yl)-piperidine-1-yl]-propoxy}-3-methoxy-phenyl)-ethyl ester as yellow oil with the optical rotation $[\alpha] -42.2^\circ$ ($c=0.5$, methanol, $T=20^\circ\text{C}$, 589 nm); e.e. 97.2 %. The oxalate has a melting point of 99-100.3°C.

The following compounds of formula I are produced analogously to Example 1:

Example	R	¹³ C-NMR C=O (ppm)	IR (C=O) cm ⁻¹	opt. Rot.	conc.	solv.
2	-(CH ₂) ₈ -CH ₃	173.150	1733	-42.2	0.5	Methanol
3	-CH ₃	169.97	1728	-43.9	0.5	Methanol
4	-C ₃ H ₇	172.47	1730	-40.3	0.6	Methanol
5	-(CH ₂) ₆ -CH ₃	173.105	1732	-30.4	0.6	Methanol
6	-(CH ₂) ₁₀ -CH ₃	173.161	1733	-40.0	0.7	Methanol
7	-(CH ₂) ₁₂ -CH ₃	173.138	1729	-37.0	0.5	Methanol
8	-(CH ₂) ₁₄ -CH ₃	173.179	1729	-34.5	0.6	Methanol
9	-CH ₂ -(CH ₂ -CH=CH) ₆ -CH ₂ -CH ₃	172.392	1734			
10	-(CH ₂) ₂ -(CH ₂ -CH=CH) ₅ -CH ₂ -CH ₃	172.008	1733			


CLAIMS

1. A compound of formula I




wherein R is (C₁₋₄₀)alkyl or (C₁₋₄₀)alkenyl, in free base or acid addition salt form.

2. A process for the production of the compounds of formula I as defined in claim 1, and their salts, comprising the step of reacting a compound of formula II



with a compound of formula III



wherein R is as defined in claim 1 and X is halogen, and recovering the resulting compound in free base or acid addition salt form.

3. A compound of claim 1 or 2 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
4. A compound of claim 1 or 2 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of psychotic disorders.

5. A pharmaceutical composition comprising a compound of claim 1 or 2 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
6. The use of a compound of claim 1 or 2 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of psychotic disorders.
7. The use of a compound of claim 1 or 2 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of psychotic disorders.
8. A method for the treatment of psychotic disorders in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 or 2 in free base or pharmaceutically acceptable acid addition salt form.



PCT/EP2004/010938

